Research in contextEvidence before this studyPancreatic ductal adenocarcinoma (PDAC) features pronounced desmoplasia with abundant extracellular matrix (ECM) components such as collagen and hyaluronic acid that promote tumourigenesis and impede drug delivery and response. Secreted protein acidic and rich in cysteine (SPARC) is a matricellular protein that is expressed in bone, testis and connective tissues. SPARC has been functionally implicated in wound healing and collagen deposition. Interestingly, SPARC is highly expressed by peritumoural fibroblasts in PDAC. Recent high-throughput sequencing technologies have identified SPARC as a marker for the activated stroma subtype in human PDAC that correlates with poor prognosis. However, SPARC has not been investigated in genetically engineered mouse models at different precursor stages of PDAC to determine its contribution to progression and therapeutic resistance.Added value of this studyThe present study provides evidence that global SPARC ablation results in significantly reduced collagen deposition around PanIN lesions and tumours in the Kras^G12D^ mouse model. Notably, SPARC dependent collagen deposition did not affect pancreatic intraepithelial neoplasia (PanIN) to PDAC progression, vascularity, proliferation, apoptosis rate, or metastatic frequency. Despite a lower tumour frequency in KC-*SPARC*^*−/−*^ mice, median survival was significantly shortened compared to KC-*SPARC*^*WT*^. This phenotype was likely caused by more severe clinical symptoms such as diarrhoea, jaundice and ascites upon tumour induction in KC-*SPARC*^*−/−*^. Despite the prevailing hypothesis that the ECM matrix impedes drug delivery and efficacy in PDAC, liquid chromatography-tandem mass spectrometry (LC-MS/MS) and immunohistochemistry revealed comparable pharmacokinetic and pharmacodynamics characteristics for gemcitabine in KC-*SPARC*^*WT*^and KC-*SPARC*^*−/−*^ mice.Implications of all the available evidenceWe have investigated the role of global SPARC depletion during different stages of pancreatic tumourigenesis. Our findings show that global SPARC depletion results in comparable PanIN and tumour growth kinetics despite a more severe clinical phenotype in KC-*SPARC*^*−/−*^ mice. Furthermore, our data contradict the prevailing hypothesis that the dense-collagen matrix restricts access of gemcitabine to the tumour. Thus, our findings may have direct translational implications in clinical trial design.Alt-text: Unlabelled Box

1. Introduction {#s0020}
===============

Histologically, PDAC is characterised by abundant stroma that harbours inflammatory cells (e.g. myeloid cells), cancer-associated fibroblast (CAFs), and large amounts of extracellular matrix (ECM) components, in particular collagen and hyaluronic acid \[[@bb0005][@bb0010]\]. The extensive tumour stroma was shown to contribute towards tumour progression, therapeutic resistance and poor prognosis in PDAC \[[@bb0015][@bb0020]\]. However, it is still unclear which components of the tumour stroma contribute to disease progression, and whether this is dependent on deposition of certain ECM components during pancreatic intraepithelial neoplasia (PanIN)-PDAC progression. To this end, several preclinical experiments suggest that pharmacological depletion or remodelling of acellular components such as hyaluronic acid and collagen increases delivery of and response to antineoplastic agents \[[@bb0025], [@bb0030], [@bb0035], [@bb0040], [@bb0045], [@bb0050]\]. On the other hand, recent data show no correlation between intra-tumoural gemcitabine concentrations and overall survival in a preclinical study using genetically engineered mice thus casting doubt on the biophysical drug barrier hypothesis \[[@bb0055]\]. Furthermore, the failure of numerous clinical trials using anti-stromal agents (e.g. sonic hedgehog inhibitors, matrix metalloproteinase, MMP inhibitors) has further dampened the initial euphoria of the stromal depletion strategy and fuelled scepticism whether the stromal barrier hypothesis is correct \[[@bb0060]\].

SPARC is an important matricellular protein that is overexpressed in peritumoural fibroblasts and has been associated with collagen deposition and the activated stroma subtype in PDAC \[[@bb0065][@bb0070]\]. High expression of SPARC in peritumoural fibroblasts is associated with a poor prognosis in PDAC patients \[[@bb0075]\]. Moreover, SPARC was proposed as a negative predictive factor for the treatment with gemcitabine \[[@bb0080]\]. Whether these clinical findings are causally related to SPARC or just associated with a more desmoplastic phenotype remains unanswered. Moreover, preclinical data from different mouse models show conflicting results regarding the role of SPARC in PDAC \[[@bb0085], [@bb0090], [@bb0095], [@bb0100], [@bb0105]\].

To investigate the role of SPARC in PDAC progression, drug delivery and response, we employed the *LSL-Kras*^*G12D/+*^; p48*-Cre* (KC) mouse model that develops PanIN lesions at 3--4 months of age and progresses to invasive PDAC after a latency of 12--15 months \[[@bb0110]\]. Progression to PDAC is accompanied by the development of a pronounced tumour microenvironment (TME) in which ECM components such as collagen and hyaluronic acid increasingly accumulate. To test the potential of SPARC as a biomarker for gemcitabine treatment, we used a recently established and validated liquid chromatography-mass spectrometry/mass spectrometry (LC-MS/MS) assay \[[@bb0115], [@bb0120], [@bb0125]\], the most sensitive method to quantify gemcitabine metabolites in small tissue biopsies, and assess response in pancreatic tumour tissues from KC-*SPARC*^*−/−*^ and KC-*SPARC*^*WT*^ mice.

2. Material and methods {#s0025}
=======================

2.1. Genetically engineered mouse models {#s0030}
----------------------------------------

*SPARC*^*−/−*^ mice (B6;129S-*Sparc*^*tm1we*^/J) were purchased from Charles River (Margate, UK) \[[@bb0130]\]. *LSL-Kras*^*G12D*^;*p48-Cre* (KC) mice (129Sv and C57BL/6) were obtained from the Tuveson group \[[@bb0110]\]. KC mice develop acinar to ductal metaplasia (ADMs) and PanINs at an early age and slowly progress to advanced and metastatic PDAC after a long latency (usually \>12 months) \[[@bb0110]\]. The model recapitulates the full spectrum of histopathological and clinical features of human PDAC. *Kras*^*G12D*^ and *p48-Cr*e mice were both crossed with *SPARC*^*−/−*^ mice, and subsequent crossing of Kras^G12D^;*SPARC*^*+/−*^ mice with *p48-Cre*;SPARC^+/−^ mice resulted in KC-*SPARC*^*W*T^ and KC-*SPARC*^*−/−*^ mice with a mixed background (129SvJ and C57BL/6). All animal experiments were carried out using protocols approved by the Institutional Animal Care and Use Committee at the University Medical Centre Göttingen. Mice were housed at a 12 h light, 12 h dark rhythm.

2.2. Therapeutic intervention and survival studies {#s0035}
--------------------------------------------------

KC-*SPARC*^*WT*^ and KC-*SPARC*^*−/−*^ mice were subjected to treatment after detection of pancreatic tumours of at least 0.5 cm as described before \[[@bb0135]\]. For pharmacokinetic studies, 12--15 months old KC-*SPARC*^*WT*^ and KC-*SPARC*^*−/−*^ mice were treated with gemcitabine (100 mg/kg body weight) once. Gemcitabine hydrochloride (Sigma, USA) was resuspended in sterile normal saline at 10 mg/ml. All tissues were harvested 2 h after the last gemcitabine dose for further analysis as previously described \[[@bb0125]\]. The 2 h time point was previously found to be the Tmax for intratumoural dFdCTP in KPC pancreatic tumours \[[@bb0115][@bb0125]\]. For survival analysis, endpoint criteria for KC-*SPARC*^*WT*^ and KC-*SPARC*^*−/−*^ were defined as 20% body weight loss, general morbidity, lethargy, lack of social interaction or development of ascites.

2.3. Liquid chromatography-mass spectrometry/mass spectrometry (LC-MS/MS) {#s0040}
-------------------------------------------------------------------------

Fresh frozen tumour samples were homogenised and extracted in 50% acetonitrile with 25 µg/ml tetrahydrouridine (THU, Calbiochem). Samples were then prepared and analysed in one batch as previously described \[[@bb0115][@bb0120]\]. Briefly, a standard curve was generated using standards of known concentration of each analyte spiked into blank tumour homogenate, and quality control samples (at lower limit of quantification, low, medium and high concentration) were included at the beginning and end of the run to confirm batch acceptance. LC-MS/MS for gemcitabine (dFdC), dFdU and dFdCTP was performed using PGC Hypercarb columns (Thermo Fisher Scientific, UK) and a Thermo Scientific TSQ Vantage triple stage quadrupole mass spectrometer with Vanquish Quaternary UPLC, data acquired with LC Quan 2.5.6.

2.4. Cell lines {#s0045}
---------------

Murine CAFs and cancer cells were isolated from freshly isolated pancreata derived from KC-*SPARC*^*WT*^ and KC-*SPARC*^*−/−*^ mice as previously described and maintained in DMEM (Invitrogen, USA) +10% FBS and 1% non-essential amino acids. (Thermo Fisher, USA). \[[@bb0055]\]. The following human pancreatic cancer cell lines were used: L3.6pl, Panc-1, Capan-1, Bxpc-3. Two immortalised human pancreatic stellate cell lines were used as previously described and abbreviated PSC1 \[[@bb0140]\], and PSC2 \[[@bb0145]\].

2.5. Western blot analysis {#s0050}
--------------------------

Western blot analysis was performed as previously described \[[@bb0055]\]. The following primary antibodies were used: Hsp90 (Cell signaling, USA, \#4875, RRID: AB_2233331), SPARC (R&D Systems, USA \#AF942, RRID: [AB_2286625](nif-antibody:AB_2286625){#ir0005}), mAb SPARC (D10F10, Cell Signaling; RRID: [AB_10860770](nif-antibody:AB_10860770){#ir0010}), and collagen I (Abcam, ab21286, RRID: AB_446161). Membranes were incubated with secondary HRP-antibodies (Jackson ImmunoResearch, USA) and developed using chemiluminescence substrate Plus-ECL (PerkinElmer Inc., USA) and protein bands were detected at the ChemiDoc™ XRS+ imaging system (Bio-Rad Laboratories GmbH, Germany) using Image Lab Software (version 5.2.1, RRID: SCR 014210).

2.6. Histological examination and laser fluorescence microscopy {#s0055}
---------------------------------------------------------------

Tissues were fixed in 10% neutral buffered formalin (Sigma) for 24 h and transferred to 70% ethanol. Tissues were embedded in paraffin, and 3--5 µm sections were processed for H&E staining, immunohistochemistry and co-immunofluorescence using standard protocols as previously described \[[@bb0150]\]. The following antibodies and kits were used: SPARC (R&D Systems, AF942, 1:100, RRID: [AB_2286625](nif-antibody:AB_2286625){#ir0015}), α-SMA (Dako, Clone 1A4, 1:250, RRID: AB_2335694), CC3 (Cell signaling, 9664L, 1:100, RRID: AB_2070042) and Ki67 (Thermo Scientific, RM-9106, 1:200, RRID: [AB_2341197](nif-antibody:AB_2341197){#ir0020}), CD31 (BD Biosciences, 553370, 1:100, RRID: [AB_394816](nif-antibody:AB_394816){#ir0025}). Pictures were taken with 40× magnification with an Olympus DP27 camera and the Olympus cellSens Entry 1.12 software.

2.7. Extracellular matrix stains {#s0060}
--------------------------------

The following reagents were used for special extracellular matrix stains: Picrosirius Red Stain Kit (Polysciences Inc., Cat. 24901-250), Masson trichrome staining kit (Polysiences Inc., Cat. 25088-1), Weigert\'s iron hematoxylin kit (Sigma) and hyaluronic acid binding protein (Calbiochem, Cat. 385911). The stainings were performed according to standard protocols on formalin fixed, paraffin embedded mouse tissues. Images were acquired as described above.

2.8. Methods of quantification {#s0065}
------------------------------

### 2.8.1. Automated quantification {#s0070}

Automated quantification of picrosirius, hyaluronic acid and α-SMA staining area was conducted by using Fiji/ImageJ (Fiji, RRID: SCR 002285) applying a low threshold to account for background staining of necrotic tumour areas. For Masson trichrome, CD31 and herovici stainings, automated quantification was performed using the Ariol SL-50 and Aperio XT automated scanning system and Imagescope 10 software (Leica Biosystems, Germany) as described previously \[[@bb0155]\].

### 2.8.2. Manual quantification {#s0075}

The following IHC data were manually quantified by counting positive stained cells for CC3 and Ki67 at least 5 HPFs (40× per slide) divided by the number of all nuclei as determined by ImageJ. PanIN and ADM lesions from early (3--4 months old) and late (7--8 months old) KC-*SPARC*^*WT*^ and KC-*SPARC*^*−/−*^ mice were semi-quantitatively scored by an expert pancreas pathologist (B.S.) with score 0: normal tissue/no PanIN/no ADM, score 1: \<30% ADMs/PanINs of total pancreas tissue area, score 2: 30--70% ADMs/PanINs, score 3: \> 70% ADMs/PanINs of total tissue area. For metastasis quantification, 5 serial H&E liver sections were quantified for metastatic burden. Liver metastases ranging from 100 to 200 µm were arbitrarily considered micro-metastases, \>200 µm as macro-metastases. Each macro-metastasis was multiplied by 3 for the final metastatic score to account for the different size.

2.9. Statistical analysis {#s0080}
-------------------------

Data are presented as mean ± SD. Statistical analysis was performed using GraphPad Prism 7.03a, (RRID: SCR 002798). *p* \< .05 Was considered statistically significant. The individual statistical tests are separately indicated in the figure legends.

3. Results {#s0085}
==========

3.1. SPARC is expressed early during PanIN development, mediates collagen deposition but does not affect PanIN-PDAC progression {#s0090}
-------------------------------------------------------------------------------------------------------------------------------

To investigate the effects on ECM formation, PanIN progression and drug delivery upon oncogenic Kras^G12D^ activation, we crossed SPARC^−/−^ mice (B6;129S-Sparc^tm1Hwe^/J) with KC mice to obtain KC-*SPARC*^*−/−*^ and KC-*SPARC*^*WT*^ control mice. Germline SPARC ablation did not impair normal pancreas development and weight ([Fig. 1](#fig0005){ref-type="fig"}A, B). In analogy to humans, immunohistochemistry revealed no expression in healthy pancreas tissue, whereas SPARC was expressed in activated fibroblasts around PanINs and in the tumour stroma of invasive murine PDAC ([Fig. 1](#fig0005){ref-type="fig"}C).Fig. 1A: Representative H&E stainings of 10 months old *SPARC*^*−/−*^ mice and control wildtype mice show normal histological architecture of the pancreas. B: Pancreas weight of *SPARC*^*−/−*^ mice (*n* = 6) and control wildtype mice (*n* = 6)(*p* = .1, Mann-Whitney-*U* test). C: SPARC immunohistochemistry in KC-*SPARC*^*WT*^ mice shows robust expression in fibroblasts around PanINs (left upper panel) and cancer associated fibroblasts (right upper panel). Lower panel reveals no immunoreactivity for SPARC in KC-*SPARC*^*−/−*^ mice. D: H&E stainings of KC-*SPARC*^*WT*^ and KC-*SPARC*^*−/−*^mice from early and late PanINs. E: Masson trichrome (MT) and Herovici staining in pancreata from KC-*SPARC*^*WT*^ and KC-*SPARC*^*−/−*^ reveals depletion of collagen matrix (blue), and reduction of mature collagen fibres (red) in KC-SPARC^−/−^ mice (7--8 months). F: Automated quantification of MT staining in KC-*SPARC*^*WT*^ (*n* = 7) and KC-*SPARC*^*−/−*^ (*n* = 10) (*p* \< .001, Mann-Whitney-U test). (For interpretation of the references to colour in this figure legend, the reader is referred to the web version of this article.)Fig. 1

Subsequently, we separated both KC-*SPARC*^*−/−*^ and KC-*SPARC*^*WT*^ mice into two cohorts to assess the role of SPARC during different stages of PanIN progression: early ADM and PanIN progression (3--4 months old, *n* ≥ 7 mice per cohort), and advanced PanIN lesions (7--8 months old, *n* ≥ 8 mice per cohort) ([Fig. 1](#fig0005){ref-type="fig"}D). Notably, SPARC ablation resulted in a dramatic reduction in overall and mature collagen ([Fig. 1](#fig0005){ref-type="fig"}E, F; *p* \< .001).

In line with immunohistochemistry, isolation of fibroblasts and epithelial cells from advanced PanIN lesions from both genotypes (*n* = 2 for each genotype) showed no expression of SPARC in epithelial cells, and strong expression in fibroblasts derived from KC-*SPARC*^*WT*^ ([Fig. 2](#fig0010){ref-type="fig"}A). Comparable results were obtained from a set of human PDAC cell lines and PSCs by Western blot analysis ([Suppl Fig. 1](#fig0025){ref-type="graphic"}A).

Notably, as SPARC regulates collagen deposition in vivo, but not collagen secretion, collagen levels were comparable between the two genotypes in cultured fibroblasts ([Fig. 2](#fig0010){ref-type="fig"}A).Fig. 2A: Western blot analysis showing robust SPARC expression in isolated fibroblasts from KC-*SPARC*^*WT*^ with simultaneous collagen-I expression, whereas fibroblasts from KC-*SPARC*^*−/−*^ and epithelial tumour cells are devoid of SPARC expression (*n* = 2 for each cell line). KC-*SPARC*^*−/−*^ fibroblasts express collagen as SPARC is not involved in collagen synthesis but assembly and deposition. B, C: Semiquantitative analysis (score 0--3) of early (3--4 months old) and late (7--8 months old) ADM and PanIN I-II lesions in KC-*SPARC*^*WT*^ (*n* = 7/8) and KC-*SPARC*^*−/-*^ (*n* = 10/11) mice. D: Immunohistochemistry for α-SMA and Ki67 in PanIN+ADM pancreatic tissue from KC-*SPARC*^*WT*^ and KC-*SPARC*^*−/−*^mice (3--4 months old). E: Automated quantification of α-SMA immunohistochemistry in preneoplastic tissues from KC-*SPARC*^*WT*^ and KC-*SPARC*^*−/−*^ mice (3--4 months old). F: Manual quantification of Ki67 immunohistochemistry showing no significant differences between KC-*SPARC*^*W*T^ and KC-*SPARC*^*−/−*^mice (3--4 months old). G: Automated quantification of CD31 immunohistochemistry in preneoplastic tissues from KC-*SPARC*^*WT*^ (*n* = 7) and KC-*SPARC*^*−/−*^ (*n* = 10) mice (3--4 months old, *p*-values all calculated by Mann-Whitney-*U* test).Fig. 2

Semi-quantitative pathological scoring (0--3) revealed no significant differences in ADM and PanIN progression upon SPARC depletion at both time points ([Fig. 2](#fig0010){ref-type="fig"}B, C).

Additional immuno-histochemical analysis showed no significant changes in α-SMA positive fibroblasts or overall proliferation rate ([Fig. 2](#fig0010){ref-type="fig"}D--F). Moreover, mean vessel density (CD31) was unchanged in PanINs and ADMs upon SPARC ablation ([Fig. 2](#fig0010){ref-type="fig"}G). This is in contrast to previous data where lack of SPARC enhanced vascular function in an orthotopic mouse model of PDAC \[[@bb0095]\].

3.2. SPARC ablation significantly reduces survival in the KC mouse model and reveals increased frequency of tumour related symptoms {#s0095}
-----------------------------------------------------------------------------------------------------------------------------------

In order to investigate the effects of peritumoural SPARC as marker for the "activated" tumour stroma, we aged KC-*SPARC*^*−/−*^ (*n* = 53) and KC-*SPARC*^*WT*^ control mice (*n* = 29) for \>12 months. Tumour development mostly occurred after 12 months (range 5--21 months). Tumour frequency in both cohorts was not significantly different for KC-SPARC^−/−^ and KC-SPARC^*WT*^ mice (49% vs. 65%, [Fig. 3](#fig0015){ref-type="fig"}A). Tumour related survival was defined according to established endpoint criteria such as ascites, inactivity, jaundice, and significant weight loss. In a separate survival cohort, tumour bearing KC-*SPARC*^*−/−*^ (*n* = 25) showed a significantly shortened survival from birth compared to tumour bearing KC-*SPARC*^*WT*^ mice (*n* = 16; 280d vs 485d, *p* \< .03, Log-rank test, [Fig. 3](#fig0015){ref-type="fig"}B). Tumour tissue was analysed regarding ECM formation and showed a dramatic reduction in collagen content and organization ([Fig. 3](#fig0015){ref-type="fig"}C--E).Fig. 3A: PDAC frequency in KC-*SPARC*^*WT*^ (*n* = 29, 65% tumour frequency) and KC-*SPARC*^*−/−*^ (*n* = 53; 49% tumour frequency, *p* = .1, Fishers Exact test). B: Survival analysis of tumour bearing KC-*SPARC*^*WT*^ (*n* = 16) and KC-*SPARC*^*−/−*^ (*n* = 25) mice shows significantly reduced survival of KC-SPARC^−/−^mice (280 days versus 485 days, *p* = .02, log-rank-test). C: Masson trichrome (MT) and picrosirius red staining in pancreatic tumours derived from KC-*SPARC*^*WT*^ and KC-*SPARC*^*−/−*^mice shows reduced overall collagen, in particular collagen I and III (picrosirius red). D: Automated quantification of MT in tumours from KC-*SPARC*^*WT*^ (*n* = 8) and KC-*SPARC*^*−/−*^ (*n* = 17) mice (*p* \< .05, Mann Whitney *U* test) E: Automated quantification of picrosirius red in tumours from KC-*SPARC*^*WT*^ (*n* = 7) and KC-*SPARC*^*−/−*^ (*n* = 18) mice. Collagen is significantly reduced in KC-SPARC^−/−^ mice (*p* = .01; Mann Whitney U test). F: Automated quantification of α-SMA immunohistochemistry in tumours from KC-*SPARC*^*WT*^ (*n* = 8) and KC-*SPARC*^*−/−*^ (*n* = 16) mice (*p* = .7, Mann-Whitney-U test). (For interpretation of the references to colour in this figure legend, the reader is referred to the web version of this article.)Fig. 3

However, SPARC nullizygosity neither affected the proportion of α-SMA positive fibroblasts nor intratumoural hyaluronic acid accumulation ([Fig. 3](#fig0015){ref-type="fig"}F, [Suppl Fig. 1](#fig0025){ref-type="graphic"}B, C). Furthermore, tumour proliferation and apoptosis rate were not significantly changed between the two cohorts of mice ([Suppl Fig. 1](#fig0025){ref-type="graphic"}D, E). All tumours were graded from G1-G4 with the majority of tumours being G2 for KC-SPARC^−/−^ (13/23; 57%) and KC-SPARC^WT^ (10/18; 56%) and no apparent association of SPARC expression and differentiation.

3.3. Clinical symptoms are more severe in KC-SPARC^−/−^ mice, but frequency of liver metastasis is not affected by SPARC ablation {#s0100}
---------------------------------------------------------------------------------------------------------------------------------

Since macrophage derived SPARC was shown to be involved in metastasis formation using an orthotopic model \[[@bb0160]\], we quantified micro- and macro-metastases to the liver, however, no significant difference was observed upon SPARC depletion ([Fig. 4](#fig0020){ref-type="fig"}A, B). Notably, clinical symptoms such as ascites, jaundice and diarrhoea occurred more frequently in KC-*SPARC*^*−/−*^ ([Table 1](#tbl0005){ref-type="table"}), providing a possible explanation for the shortened survival despite the comparable tumour kinetics.Fig. 4A: H&E staining from micro-metastases (circles left picture) and macro-metastases of the liver in KC-SPARC^WT^ mice. B: Manual quantification of macro- and micro-metastases in KC-SPARC^WT^ (*n* = 10) and KC-SPARC^−/−^ (*n* = 15). C + D Tumour tissues from KC-*SPARC*^*WT*^ (*n* ≥ 5) and KC-*SPARC*^*−/−*^ mice (*n* = 10) were assessed for gemcitabine metabolites 2 h after injection of 100 mg/kg gemcitabine by LC-MS/MS. Native gemcitabine (dFdC) and the active form of gemcitabine 2′,2′-difluorodeoxyuridine-5′-triphosphate (dFdCTP) were not significantly altered between the two genotypes. E: Manual quantification of CC3 immunohistochemistry in tumours from KC-*SPARC*^*WT*^ (*n* = 6) and KC-*SPARC*^*−/−*^ (*n* = 6) mice upon 1 dose of gemcitabine at 100 mg/kg. Mann-Whitney-U test was used for calculation of *p*-values.Fig. 4Table 1Clinical symptoms in KC-*SPARC*^*WT*^ (*n* = 18) and KC-*SPARC*^*−/−*^ (*n* = 26) mice showing a more severe phenotype in KC-*SPARC*^*−/−*^ mice.Table 1Clinical signsKC-*SPARC*^*−/−*^ (*n* = 26)KC-*SPARC*^*WT*^ (*n* = 18)Ascites4 (15%)0Jaundice4 (15%)1Diarrhoea2 (8%)0[^1]

3.4. SPARC ablation and subsequent collagen reduction in murine PDAC does not impair gemcitabine delivery or immediate efficacy {#s0105}
-------------------------------------------------------------------------------------------------------------------------------

Since SPARC was suggested as negative predictive factor for the treatment with gemcitabine \[[@bb0080]\], we investigated whether SPARC dependent collagen deposition would impinge on gemcitabine metabolism and effectiveness. To this end, we treated tumour-bearing 12--15 months old KC-*SPARC*^*−/−*^ (*n* = 10) and KC-*SPARC*^*WT*^ mice (*n* = 6) with a single dose of 100 mg/kg gemcitabine. Pancreatic tumour samples were taken 2 h after gemcitabine administration as previous data had shown that peak gemcitabine levels and gemcitabine induced cell death were reached after 2 h \[[@bb0125]\].

Tumour samples were subjected to LC-MS/MS analysis and showed no significant differences for the gemcitabine prodrug 2′,2′-difluorodeoxycytidine (dFdC) as well as for the activated and cytotoxic form of gemcitabine 2′,2′-difluorodeoxycytidine-5′-triphosphate (dFdCTP) despite the differences in collagen content ([Fig. 4](#fig0020){ref-type="fig"}C, D). Furthermore, the immediate therapeutic response did not differ between KC-*SPARC*^*−/−*^ and KC-*SPARC*^*WT*^ tumours as evidenced by a comparable number of cleaved-caspase 3 positive tumour cells ([Fig. 4](#fig0020){ref-type="fig"}E).

4. Discussion {#s0110}
=============

PDAC is characterised by the accumulation of large amounts of ECM components such as collagen and hyaluronic acid, as well as abundant fibro-inflammatory cells that surround neoplastic cells at large numbers. Over the last years, accumulating evidence suggests that the tumour stroma can both restrain and promote disease progression and therapeutic resistance \[[@bb0035][@bb0165][@bb0170]\]. However, due to the complex composition of cellular and acellular components of the stroma, it is often not clear which components accelerate and attenuate tumour progression. Furthermore, a highly debated and largely unsolved question is whether this desmoplastic reaction in PDAC creates biophysical barriers for drug delivery that may, at least partly, explain the highly chemoresistant phenotype of human PDAC. Consequently, despite several promising preclinical approaches to therapeutically target the tumour stroma \[[@bb0025], [@bb0030], [@bb0035], [@bb0040],[@bb0050][@bb0125]\], none of the anti-stromal compounds have so far succeeded in clinical trials \[[@bb0020]\]. Stromal and epithelial subtyping conducted by RNA sequencing and often combined with laser capture microdissection has recently revealed "activated" and "normal" stromal subtypes in PDAC patients that are strongly correlated with prognosis \[[@bb0065][@bb0175]\]. The fact that SPARC is one of the most prominently expressed transcripts in the "activated" stroma subtype that is correlated with worse survival \[[@bb0065]\], and the fact that SPARC was suggested as potential biomarker for gemcitabine response \[[@bb0080]\], led us to investigate the expression, function and preclinical relevance of peritumoural SPARC in a genetically engineered mouse model of PDAC.

Therefore, we depleted the matricellular protein SPARC that is centrally involved in collagen maturation and deposition in the KC mouse model to investigate the effect of SPARC on the PanIN-PDAC progression. Notably, our results show that SPARC ablation caused a significant reduction in overall and mature collagen deposition during preneoplastic and invasive tumour stages. Despite the fact that tumour bearing KC-*SPARC*^*−/−*^ mice lived significantly shorter compared to their tumour bearing wildtype littermates, hallmark features such as PanIN progression, epithelial cell proliferation, CAF viability, and invasiveness, angiogenesis or metastatic frequency were not altered by SPARC expression. Thus, the shortened survival may likely be caused by an increase in tumour related symptoms such as ascites, diarrhoea and jaundice, but not by more aggressive and metastatic tumours per se. This more severe phenotype might be caused by systemic effects of global SPARC depletion in mice upon tumour induction, but not specifically by alterations of stromal SPARC ablation in pancreatic tumours. Albeit not significantly, it was interesting to note that despite the worse outcome of KC-*SPARC*^*−/−*^ mice, tumour frequency was lower in KC-*SPARC*^*−/−*^ compared to KC-*SPARC*^*WT*^mice*.* Conditional genetic deletion of SPARC using a fibroblast-specific promoter such as α-SMA or collagen should be performed and might yield distinctly different results. Previous data generated in orthotopic and genetically engineered mice *(LSL-Kras*^*G12D*^*; Cdkn2a*^*lox/lox*^*; p48*^*Cre*^*)* suggest direct effects of SPARC on angiogenesis and tumour progression that could not be recapitulated in our experiments using the KC-mouse model \[[@bb0085][@bb0095]\], where ADM and PanIN lesions slowly progress, and tumour development occurs only in about 50--60% of mice. These fundamentally different growth kinetics and the more aggressive tumour biology using *LSL-Kras*^*G12D*^; *Cdkn2a*^*lox/lox*^; *p48*^*Cre*^ mice may have determined the observed phenotype.

Since SPARC was suggested as negative predictive factor for the treatment with gemcitabine \[[@bb0080]\], we investigated whether SPARC dependent collagen deposition would impinge on gemcitabine metabolism and effectiveness for the first time. In line with previously published data on nab-paclitaxel and SPARC \[[@bb0150][@bb0180][@bb0185]\], we did not see significant changes in gemcitabine pharmacokinetics and pharmacodynamics upon genetic SPARC modification.

Therefore, our data suggest that despite the observed collagen reduction, peritumoural SPARC ablation neither determines hallmark features of pancreatic tumour development and progression nor the response to gemcitabine in a genetically engineered model of autochthonous PDAC. However, one potential limitation of our mouse model is that SPARC was deficient in all cells during development thus potentially affecting the results and the phenotype of the mice. Notably, two major cell types of the TME, CAFs and tumour-associated macrophages (TAMs) were recently discovered to actively metabolise and scavenge chemotherapeutic drugs in experimental PDAC \[[@bb0055][@bb0190]\]. Our current findings on SPARC dependent collagen deposition and gemcitabine delivery are in line with these data and point towards a critical role of these cell types for future therapeutic approaches and clinical trial design.
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Appendix A. Supplementary data {#s3140}
==============================

Suppl Fig. 1A: Western blot analysis for SPARC shows robust expression in human PSC1 and PSC2 compared to low or absent expression in human PDAC cell lines. B: Hyaluronic acid staining in KC-*SPARC*^*WT*^ and KC-*SPARC*^*−/−*^ mice. C: Automated quantification of HA staining in tumours from KC-*SPARC*^*WT*^ (*n* = 8) and KC-*SPARC*^*−/−*^ (*n* = 18) mice. D: Manual quantification of Ki67 immunohistochemistry in tumours from KC-*SPARC*^*WT*^ (*n* = 7) and KC-*SPARC*^*−/−*^ (*n* = 6) mice. E: Manual quantification of CC3 immunohistochemistry in tumours from KC-*SPARC*^*WT*^ (n = 7) and KC-*SPARC*^*−/−*^ (*n* = 12) mice. Mann-Whitney-*U* test was used for calculation of *p*-values.Suppl Fig. 1
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[^1]: *p*-values for ascites (*p* = .1), jaundice (*p* = .6), and diarrhoea (*p* = .5) using Fishers Exact test.
